

University of Naples Federico II is implementing and evaluating Proclarix® to make it available in Italy

Zurich-Schlieren, Switzerland and Naples, Italy, May 04, 2021 – The University of Naples Federico II, Italy and Proteomedix, the Swiss cancer diagnostics company, announced today that **Proclarix®**, a new blood-based test for prostate cancer patient management, will be clinically evaluated and made routinely available in Italy.

"**Proclarix®** is an innovative decision support tool to improve patient management in prostate cancer diagnostics in men suspected to have prostate cancer. "We are excited to be the first clinical partner in Italy to locally implement and evaluate Proclarix", said Prof. Dr. Daniela Terracciano. "The test combines the ease-of-use and high acceptance for patients of a blood-based biomarker test and will be compared to current clinical practice".

Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. In Italy, more than 40'000 new cases of prostate cancer are diagnosed and around 7'000 prostate cancer related deaths occur each year.

"We are delighted to have the University of Naples Federico II as a partner and expect that our collaboration will help to identify men suspected to have clinically relevant prostate cancer faster", said Dr. Ralph Schiess, CSO and co-founder of Proteomedix. Schiess added: "The Proclarix' risk score has been extensively validated and it was demonstrated that it can help to reduce the number of biopsies avoiding invasive procedures, anxiety, discomfort, pain and complications.

About Proclarix®

Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining *in-vitro* assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient's risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.

About University of Naples Federico II:

The University of Naples Federico II is the oldest public university in the world and one of the most important University Hospitals in Southern Italy. Around 5'000 employees are covering all medical and surgery specialties. It has a top-level rank of publications in basic and bed-side topics. The University Hospital is closely linked to leading American and European Universities.

For further details, please contact:

Prof. Dr. Daniela Terracciano, Professor of Clinical Pathology at the Department of Translational Medicine
daniela.terracciano@unina.it, +39 081 746 3617

About Proteomedix

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product **Proclarix®** is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:

Dr. Ralph Schiess, CSO
schiess@proteomedix.com, +41 44 733 40 90